Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Bayer plea dismissed, Natco allowed to sell patent cancer drug

Bayer plea dismissed, Natco allowed to sell patent cancer drug

Share this article Share this article
published Published on Mar 5, 2013   modified Modified on Mar 5, 2013
-The Business Standard

Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India.

IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to seven per cent. The board has also imposed a penalty on Natco for filing a false statement.

In March last year, Natco got the first-ever compulsory licence to make the generic version of Nexavar. Under Indian patent law, companies can seek a compulsory licence if a patented drug is not available to the public at a reasonable price.

Bayer Corp, the US arm of German drug manufacturer Bayer AG, moved IPAB challenging the patent authority's decision. On September 17, the board had dismissed a stay petition filed by Bayer.

A coram comprising IPAB chairman justice Prabha Sridevan and technical member (patents) D P S Parmar has taken the latest decision.

The coram observed the patentee, Bayer Corp, could not sell the drug at a reasonably affordabile price.

The Controller of Patents was right in holding that the sale by the appellant at a price of Rs 2.8 lakh was not reasonably affordable, it said.

However, the board felt the royalty fixed for the compulsory licence, that is six per cent of the total sales, was not sufficient and has to be revised. "We are of the opinion of an increase of one per cent in the royalty fixed by the controller to the appellant," said Sridevan.

The coram dismissed Bayer's arguments that the presence of Cipla Ltd, which has launched a generic version of Nexavar and has begun a legal battle in the Delhi High Court, has to be taken into consideration when it comes to the supply of the drug.

IPAB also rejected Bayer's contention that Natco did not extend proper negotiation with the patent holder before filing for the compulsory licensing.

Meanwhile, Bayer has approached the Indian Patent Office, alleging non-compliance of the patent controller's compulsory licensing conditions by Natco.

The Business Standard, 5 March, 2013, http://www.business-standard.com/article/companies/bayer-plea-dismissed-natco-allowed-to-sell-patent-cancer-drug-113030500026_1.html


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close